|
KMID : 0191120160310071160
|
|
Journal of Korean Medical Science
2016 Volume.31 No. 7 p.1160 ~ p.1163
|
|
|
Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
|
|
Lee Seung-Shin
Jung Sung-Hoon
Ahn Jae-Sook
Kim Yeo-Kyeoung
Cho Min-Seok
Lee Je-Jung
Kim Hyeoung-Joon
Yang Deok-Hwan
|
|
|
Abstract
|
|
|
|
Peripheral T cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas with poor prognosis. Elderly (age ≥ 65years) patients generally have impaired bone marrow function, altered drug metabolism, comorbidities, and poor functional status. Thus, treatment of elderly patients with relapsed or refractory PTCL remains a challenge for clinicians. A recent study disclosed that pralatrexate has a synergistic effect in combination with bortezomib. Weekly pralatrexate and bortezomib were administered intravenously for 3 weeks in a 4-week cycle. Of 5 patients, one achieved complete response after 4 cycles which has lasted 12 months until now. Another patient attained partial response after 2 cycles. Only 1 patient experienced grade 3 thrombocytopenia and neutropenia. Two patients suffered from grade 3 mucositis. Combination therapy with pralatrexate and bortezomib may be used as a salvage therapy for relapsed or refractory PTCL in the elderly with a favorable safety profile.
|
|
|
KEYWORD
|
|
|
Peripheral T Cell Lymphoma, Pralatrexate, Bortezomib, Elderly
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|